Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Q58073610)

Rajith Kumar Reddy Rajoli

2

0 references

Darren M. Moss

Darren Moss

5

0 references

Adeniyi Olagunju

Adeniyi Olagunju

4

0 references

Marco Siccardi

Marco Siccardi

1

0 references

Andrew Owen

Andrew Owen

6

0 references

author name string

Paul Curley

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

3

0 references

publication date

September 2013

0 references

published in

Future Virology

0 references

volume

8

0 references

page(s)

871-890

0 references

issue

9

0 references

cites work

1 reference

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients

21 January 2018

1 reference

Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.

21 January 2018

1 reference

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study

21 January 2018

1 reference

Ageing with HIV: medication use and risk for potential drug-drug interactions

21 January 2018

1 reference

An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry

21 January 2018

1 reference

Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis

21 January 2018

1 reference

Physiologically-based pharmacokinetics in drug development and regulatory science

21 January 2018

1 reference

Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.

21 January 2018

1 reference

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA

21 January 2018

1 reference

Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice

21 January 2018

1 reference

Cytochrome P450-mediated metabolism in the human gut wall

21 January 2018

1 reference

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

21 January 2018

1 reference

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

21 January 2018

1 reference

Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma

21 January 2018

1 reference

An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.

21 January 2018

1 reference

Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

21 January 2018

1 reference

The Simcyp population-based ADME simulator

21 January 2018

1 reference

Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

21 January 2018

1 reference

Enrolling pregnant women: issues in clinical research

21 January 2018

1 reference

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach

21 January 2018

1 reference

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

21 January 2018

1 reference

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.

21 January 2018

1 reference

Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes.

21 January 2018

1 reference

Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

21 January 2018

1 reference

A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

21 January 2018

1 reference

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction

21 January 2018

1 reference

The problems in scaling adult drug doses to children.

21 January 2018

1 reference

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda

21 January 2018

1 reference

A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam

21 January 2018

1 reference

Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs

21 January 2018

1 reference

Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland

21 January 2018

1 reference

Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion

21 January 2018

1 reference

HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group

21 January 2018

1 reference

The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa

21 January 2018

1 reference

Pharmacokinetics in older persons

21 January 2018

1 reference

Pharmacologic consideration for the use of antiretroviral agents in the elderly

21 January 2018

1 reference

Pharmacokinetics and drug metabolism in the elderly

21 January 2018

1 reference

Clinical pharmacokinetics of antiretroviral drugs in older persons

21 January 2018

1 reference

P-glycoprotein function at the blood-brain barrier: effects of age and gender

21 January 2018

1 reference

Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration

21 January 2018

1 reference

The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes

21 January 2018

1 reference

21 January 2018

1 reference

Free drug metabolic clearance in elderly people.

21 January 2018

1 reference

Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly

21 January 2018

1 reference

The burden of liver disease in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

21 January 2018

1 reference

Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis.

21 January 2018

1 reference

Protein Binding and Kinetics of Drugs in Liver Diseases

21 January 2018

1 reference

Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis

21 January 2018

1 reference

Renal failure in cirrhosis

21 January 2018

1 reference

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

21 January 2018

1 reference

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

21 January 2018

1 reference

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

21 January 2018

1 reference

Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis

21 January 2018

1 reference

Increasing rates of obesity among HIV-infected persons during the HIV epidemic

21 January 2018

1 reference

Effect of obesity on the pharmacokinetics of drugs in humans

21 January 2018

1 reference

The effects of obesity on drug pharmacokinetics in humans

21 January 2018

1 reference

Drug interactions between antiretrovirals and hormonal contraceptives.

21 January 2018

1 reference

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

21 January 2018

1 reference

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults

21 January 2018

1 reference

Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz

21 January 2018

1 reference

Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers

21 January 2018

1 reference

Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration

21 January 2018

1 reference

Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz

21 January 2018

1 reference

In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters

21 January 2018

1 reference

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir

21 January 2018

1 reference

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.

21 January 2018

1 reference

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.

21 January 2018

1 reference

Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population

21 January 2018

1 reference

Prevalence of HIV and chronic comorbidities among older adults

21 January 2018

1 reference

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

21 January 2018

1 reference

Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents

21 January 2018

1 reference

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension

21 January 2018

1 reference

Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation

21 January 2018

1 reference

Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects

21 January 2018

1 reference

Effects of omeprazole on plasma levels of raltegravir

21 January 2018

1 reference

Population-based mechanistic prediction of oral drug absorption

21 January 2018

1 reference

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

21 January 2018

1 reference

Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS).

21 January 2018

1 reference

Predicting intestinal absorption of raltegravir using a population-based ADME simulation

21 January 2018

1 reference

Divalent metals and pH alter raltegravir disposition in vitro

21 January 2018

1 reference

Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers

21 January 2018

1 reference

A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution

21 January 2018

1 reference

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

21 January 2018

1 reference

Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract

21 January 2018

1 reference

Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging

21 January 2018

1 reference

The gastrointestinal microbiota as a site for the biotransformation of drugs

21 January 2018

1 reference

Microbial ecology: human gut microbes associated with obesity

21 January 2018

1 reference

Overcoming pharmacologic sanctuaries

21 January 2018

1 reference

Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure

21 January 2018

1 reference

Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir

21 January 2018

1 reference

Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination

21 January 2018

1 reference

The expression and function of organic anion transporting polypeptides in normal tissues and in cancer

21 January 2018

1 reference

Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR.

21 January 2018

1 reference

Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines.

21 January 2018

1 reference

Development of a computational approach to predict blood-brain barrier permeability.

21 January 2018

1 reference

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

Anti-HIV drug distribution to the central nervous system

21 January 2018

1 reference

Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats.

21 January 2018

1 reference

Pharmacogenetics of HIV therapy

21 January 2018

1 reference

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

21 January 2018

1 reference

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

The impact of pharmacogenetics on HIV therapy

21 January 2018

1 reference

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine

21 January 2018

1 reference

Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine

21 January 2018

1 reference

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

21 January 2018

1 reference

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

21 January 2018

1 reference

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

21 January 2018

1 reference

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

21 January 2018

1 reference

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

21 January 2018

1 reference

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

Efavirenz in the therapy of HIV infection.

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.

21 January 2018

1 reference

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

21 January 2018

1 reference

Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection

21 January 2018

1 reference

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers

21 January 2018

1 reference

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals

21 January 2018

1 reference

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

21 January 2018

1 reference

Pharmacogenetics of tenofovir treatment

21 January 2018

1 reference

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

21 January 2018

1 reference

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

21 January 2018

1 reference

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

21 January 2018

1 reference

Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues

21 January 2018

1 reference

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

21 January 2018

1 reference

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

21 January 2018

1 reference

Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor

21 January 2018

1 reference

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir

21 January 2018

1 reference

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

21 January 2018

1 reference